Teva Pharmaceutical Industries Limited (TEVA) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Teva's CEO, Richard Francis, reported 10 consecutive quarters of growth, underscoring the success of its 'Pivot to Growth' strategy and ongoing transition into a biopharma company. Despite a 2% decline in the generics business in Q2 due to tough comparisons, the strength of innovative products like AUSTEDO and UZEDY drove increases in gross margin, EBITDA, and EPS. The company projects its schizophrenia franchise (UZEDY and upcoming olanzapine) to reach $1.5B-$2B in peak sales, while the broader pipeline, featuring the 'transformative' TL1A asset duvakitug and DARI asthma inhaler, holds an estimated $11B-$13B in total peak sales potential. Teva remains on track for its 2027 financial targets, including a 30% operating margin and 5% revenue CAGR, emphasizing disciplined capital allocation and robust pipeline execution.

Analysis

Teva's 'Pivot to Growth' strategy is demonstrating clear success, marking a fundamental transition from a generics-focused entity to an innovative biopharma company. This shift is validated by 10 consecutive quarters of growth and, more significantly, the Q2 performance where the company expanded gross margin, EBITDA, and EPS despite a 2% decline in its generics business. This proves the innovative portfolio has reached a critical mass, capable of driving profitability independently. The high-margin profile of the innovative pipeline, with gross margins reported in the 90% range compared to the current corporate average of 54%, provides a clear trajectory for significant P&L expansion as the sales mix evolves. The pipeline's potential is substantial, with an estimated $11 billion to $13 billion in total peak sales from key assets including the schizophrenia franchise (UZEDY and olanzapine, guided to $1.5B-$2B), the DARI asthma inhaler ($1B), and the 'transformative' TL1A asset, duvakitug. Management's confidence is further supported by a de-risked R&D strategy focused on proven mechanisms of action and the fact that the next major loss of exclusivity is not until 2042. The generics business is being repositioned as a stable, cash-generating foundation to fund innovation, with its overall impact on group performance set to diminish, particularly after the U.S. generics unit shrinks to 25% of the global generics business post-Revlimid LOE.

Key Decisions for Investors

• Investors should model for significant gross and operating margin expansion as the sales mix shifts towards high-margin innovative products, which carry profitability far exceeding the current company average.
• Monitor key pipeline execution catalysts, particularly the commercial launch of olanzapine by late next year and Phase III progress for the 'transformative' TL1A asset duvakitug, which underpins the long-term growth narrative.
• Re-evaluate the generics business as a source of stable cash flow for funding innovation rather than a primary growth driver, noting its diminishing impact on group earnings volatility.
• Acknowledge that Teva appears relatively insulated from near-term geopolitical risks, given its significant U.S. manufacturing footprint and a supply chain that is not heavily reliant on China or India.